HRP20100577T1 - Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti - Google Patents

Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti Download PDF

Info

Publication number
HRP20100577T1
HRP20100577T1 HR20100577T HRP20100577T HRP20100577T1 HR P20100577 T1 HRP20100577 T1 HR P20100577T1 HR 20100577 T HR20100577 T HR 20100577T HR P20100577 T HRP20100577 T HR P20100577T HR P20100577 T1 HRP20100577 T1 HR P20100577T1
Authority
HR
Croatia
Prior art keywords
agomelatine
anxiety disorder
pharmaceutically acceptable
hydrates
generalised anxiety
Prior art date
Application number
HR20100577T
Other languages
English (en)
Inventor
Delalleau Bruno
Fabiano Agnes
Millan Mark
Mocaer Elisabeth
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100577(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HRP20100577T1 publication Critical patent/HRP20100577T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uporaba agomelatina ili N-[2-(7-metoksi-1-naftil)etil]acetamida ili jednog od njegovih hidrata, kristalnih oblika i adicijskih soli s farmaceutski prihvatljivom kiselinom ili lužinom, kao jednim djelatnim sastojkom, naznačena time, da je za dobivanje lijeka namijenjenog za liječenje općeg poremećaja anksioznosti. Patent sadrži još 3 patentna zahtjeva.

Claims (4)

1. Uporaba agomelatina ili N-[2-(7-metoksi-1-naftil)etil]acetamida ili jednog od njegovih hidrata, kristalnih oblika i adicijskih soli s farmaceutski prihvatljivom kiselinom ili lužinom, kao jednim djelatnim sastojkom, naznačena time, da je za dobivanje lijeka namijenjenog za liječenje općeg poremećaja anksioznosti.
2. Uporaba u skladu s patentnim zahtjevom 1, naznačena time da je agomelatin dobiven u kristalnom obliku II.
3. Farmaceutske smjese koje, kao djelatni sastojci, sadrže agomelatin, ili jedan od njegovih hidrata, kristalnih oblika i adicijskih soli s farmaceutski prihvatljivom kiselinom ili lužinom, same ili u kombinaciji s jednim ili više farmaceutski prihvatljivih ekscipijensa, naznačeno time, da su za uporabu u liječenju općeg poremećaja anksioznosti.
4. Farmaceutska smjesa u skladu s patentnim zahtjevom 3, naznačena time da je agomelatin dobiven u kristalnom obliku II.
HR20100577T 2006-04-07 2010-10-21 Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti HRP20100577T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0603083A FR2899472B1 (fr) 2006-04-07 2006-04-07 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee

Publications (1)

Publication Number Publication Date
HRP20100577T1 true HRP20100577T1 (hr) 2010-11-30

Family

ID=37308935

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100577T HRP20100577T1 (hr) 2006-04-07 2010-10-21 Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti

Country Status (44)

Country Link
US (1) US7960438B2 (hr)
EP (1) EP1842535B1 (hr)
JP (1) JP4880031B2 (hr)
KR (1) KR20070100657A (hr)
CN (1) CN101049290B (hr)
AP (1) AP2488A (hr)
AR (1) AR060349A1 (hr)
AT (1) ATE477798T1 (hr)
AU (1) AU2007201527B2 (hr)
BR (1) BRPI0701601A (hr)
CA (1) CA2584060C (hr)
CO (1) CO5840252A1 (hr)
CR (1) CR9019A (hr)
CY (1) CY1111287T1 (hr)
DE (1) DE602007008494D1 (hr)
DK (1) DK1842535T3 (hr)
EA (1) EA012608B1 (hr)
ES (1) ES2351062T3 (hr)
FR (1) FR2899472B1 (hr)
GE (1) GEP20094743B (hr)
GT (1) GT200700032A (hr)
HK (1) HK1108367A1 (hr)
HR (1) HRP20100577T1 (hr)
IL (1) IL182407A (hr)
JO (1) JO3440B1 (hr)
MA (1) MA28987B1 (hr)
ME (1) ME01865B (hr)
MX (1) MX2007004100A (hr)
MY (1) MY143269A (hr)
NI (1) NI200700084A (hr)
NO (1) NO20071774L (hr)
NZ (1) NZ554347A (hr)
PE (1) PE20080174A1 (hr)
PL (1) PL1842535T3 (hr)
PT (1) PT1842535E (hr)
RS (1) RS51485B (hr)
SA (1) SA07280161B1 (hr)
SG (1) SG136881A1 (hr)
SI (1) SI1842535T1 (hr)
TN (1) TNSN07118A1 (hr)
TW (1) TWI374736B (hr)
UY (1) UY30262A1 (hr)
WO (1) WO2007116136A1 (hr)
ZA (1) ZA200702865B (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
FR2956031B1 (fr) * 2010-02-11 2012-03-02 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EP2810656B1 (en) 2013-06-06 2017-08-02 Zentiva, a.s. Agomelatine formulations comprising agomelatine in the form of co-crystals
IT201900002913A1 (it) 2019-03-01 2020-09-01 Nicola Pescosolido Composto utile per il trattamento del glaucoma
CN110867197A (zh) * 2019-10-23 2020-03-06 吴杰 语音交互过程中实时打断语音机器人的方法及设备

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
SG45100A1 (en) * 1994-03-07 1998-01-16 Ibm Improvements in image processing
DE19532842C1 (de) * 1995-09-05 1996-12-19 Ibm Bildaufnahmesystem
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
AU2004308962A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7635721B2 (en) * 2005-08-03 2009-12-22 Les Laboratoires Servier Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
FR2899472A1 (fr) 2007-10-12
IL182407A0 (en) 2008-01-20
ME01865B (me) 2011-04-30
PL1842535T3 (pl) 2011-01-31
FR2899472B1 (fr) 2008-09-12
MA28987B1 (fr) 2007-11-01
PE20080174A1 (es) 2008-03-29
EA200700574A2 (ru) 2007-10-26
JO3440B1 (ar) 2019-10-20
US7960438B2 (en) 2011-06-14
EP1842535B1 (fr) 2010-08-18
UY30262A1 (es) 2007-05-31
WO2007116136A1 (fr) 2007-10-18
KR20070100657A (ko) 2007-10-11
SG136881A1 (en) 2007-11-29
AP2488A (en) 2012-10-03
RS51485B (en) 2011-04-30
CA2584060A1 (fr) 2007-10-07
JP2009532446A (ja) 2009-09-10
CO5840252A1 (es) 2007-12-31
HK1108367A1 (en) 2008-05-09
AP2007003953A0 (en) 2007-04-30
TW200808295A (en) 2008-02-16
AU2007201527A1 (en) 2007-10-25
EA012608B1 (ru) 2009-10-30
PT1842535E (pt) 2010-09-28
ZA200702865B (en) 2008-07-30
ES2351062T3 (es) 2011-01-31
BRPI0701601A (pt) 2007-12-11
SA07280161B1 (ar) 2010-10-23
DK1842535T3 (da) 2010-11-15
US20070238792A1 (en) 2007-10-11
AU2007201527B2 (en) 2012-08-09
SI1842535T1 (sl) 2010-10-29
AR060349A1 (es) 2008-06-11
TNSN07118A1 (fr) 2008-06-02
GT200700032A (es) 2007-10-31
JP4880031B2 (ja) 2012-02-22
EA200700574A3 (ru) 2007-12-28
IL182407A (en) 2016-02-29
MY143269A (en) 2011-04-15
CA2584060C (fr) 2011-04-26
CN101049290B (zh) 2012-10-31
NZ554347A (en) 2008-08-29
GEP20094743B (en) 2009-07-27
EP1842535A1 (fr) 2007-10-10
DE602007008494D1 (de) 2010-09-30
CY1111287T1 (el) 2015-08-05
NI200700084A (es) 2008-04-24
CR9019A (es) 2008-10-28
CN101049290A (zh) 2007-10-10
TWI374736B (en) 2012-10-21
NO20071774L (no) 2007-10-08
MX2007004100A (es) 2009-02-16
ATE477798T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
HRP20100577T1 (hr) Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti
RS52922B (en) PREPARATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND THEIR USES
HRP20151443T1 (hr) Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
MX344308B (es) Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
UY26139A1 (es) Composiciones de medicamentos a base de compuestos anticolinérgicamente activos y beta- miméticos
RS54707B1 (en) TREATMENT OF CROWN LAKVINIMOD DISEASE
RU2015117267A (ru) Замещенные соединения амида
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
AR056063A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos del sueno en el paciente deprimido
EA201171109A1 (ru) Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
RU2011137131A (ru) Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
RU2009131745A (ru) Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера
HRP20120344T1 (hr) N-(2-hidroksietil)-n-metil-4-(kinolin-8-il(1-(tiazol-4-ilmetil) piperidin-4-iliden)metil)benzamid, postupak njegovog dobivanja kao i njegova uporaba za liječenje bola, tjeskobe i depresije
HRP20180537T1 (hr) Uporaba agomelatina za pripravu lijekova za liječenje opsesivno-kompulzivnog poremećaja (ocd)
HRP20110370T1 (hr) Uporaba agomelatina za dobivanje lijeka u cilju liječenja smith-magenisovog sindroma
AR041891A1 (es) Empleo de resveratrol para la preparacion de un medicamento util para el tratamiento de infecciones causadas por el virus de la influenza
RU2010107177A (ru) Новые комбинации нерамексана для лечения нейродегенеративных расстройств
CL2023002665A1 (es) Formas de dosificación farmacéuticas que comprenden (4s)–24–cloro–4–etil–73–fluoro–35–metoxi– 32,5–dioxo–14–(trifluorometil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2 (1,2),7(1)–dibencenaheptafano–74–carboxamida
HRP20110083T1 (hr) Uporaba agomelatina u proizvodnji lijeka za liječenje bipolarnih poremećaja
HRP20100680T1 (hr) Upotreba agomelatina za dobivanje lijeka u cilju lijecenja periventrikularne leukomalacije
HRP20160832T1 (hr) Liječenje osteoporoze
RU2013114246A (ru) Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении